If you are:
FDB Contraindicated or Not Recommended: FETAL DEATH/MORBIDITY W/USE IN 2ND & 3RD TRIMESTER, STOP WHEN PREGNANCY DETECTED
Only When Necessary: INSUFFICIENT HUMAN DATA AVAIL; NONTERATOGENIC EFFECTS OBSERVED IN ANIMALS
Precaution: INSUFFICIENT DATA AVAIL; CONSIDER MATERNAL TREATMENT BENEFIT VS INFANT RISK
Precaution: REPORTED AMOUNT IN BREASTMILK LESS THAN 0.1% OF MATERNAL DOSE.
An adult over 60:
management or monitoring precaution: Renal-Monitor for increased serum creatinine or hyperkalemia. Cardiovascular-Increased risk for hypotension in the elderly.
management or monitoring precaution: General-Not recommended as first line therapy in the elderly. Cardiovascular-Start at 2.5 mg/day and slowly titrate upward. Peripheral edema may be common. Lower drug clearance may result in increased sensitivity to blood pressure lowering effects. Gastrointestinal-May cause or worsen pre-existing constipation.
Giving AMLODIPINE BESYLATE-BENAZEPRIL to a child under 12:
management or monitoring precaution: No safety and efficacy data for age < 6 years.
management or monitoring precaution: No safety and efficacy of combination product in pediatrics.